Cargando…
Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we g...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433785/ https://www.ncbi.nlm.nih.gov/pubmed/28472156 http://dx.doi.org/10.1371/journal.ppat.1006359 |
_version_ | 1783236922615791616 |
---|---|
author | Fennessey, Christine M. Pinkevych, Mykola Immonen, Taina T. Reynaldi, Arnold Venturi, Vanessa Nadella, Priyanka Reid, Carolyn Newman, Laura Lipkey, Leslie Oswald, Kelli Bosche, William J. Trivett, Matthew T. Ohlen, Claes Ott, David E. Estes, Jacob D. Del Prete, Gregory Q. Lifson, Jeffrey D. Davenport, Miles P. Keele, Brandon F. |
author_facet | Fennessey, Christine M. Pinkevych, Mykola Immonen, Taina T. Reynaldi, Arnold Venturi, Vanessa Nadella, Priyanka Reid, Carolyn Newman, Laura Lipkey, Leslie Oswald, Kelli Bosche, William J. Trivett, Matthew T. Ohlen, Claes Ott, David E. Estes, Jacob D. Del Prete, Gregory Q. Lifson, Jeffrey D. Davenport, Miles P. Keele, Brandon F. |
author_sort | Fennessey, Christine M. |
collection | PubMed |
description | HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we generated a genetically tagged virus stock (SIVmac239M) with a 34-base genetic barcode inserted between the vpx and vpr accessory genes of the infectious molecular clone SIVmac239. Next-generation sequencing of the virus stock identified at least 9,336 individual barcodes, or clonotypes, with an average genetic distance of 7 bases between any two barcodes. In vitro infection of rhesus CD4+ T cells and in vivo infection of rhesus macaques revealed levels of viral replication of SIVmac239M comparable to parental SIVmac239. After intravenous inoculation of 2.2x10(5) infectious units of SIVmac239M, an average of 1,247 barcodes were identified during acute infection in 26 infected rhesus macaques. Of the barcodes identified in the stock, at least 85.6% actively replicated in at least one animal, and on average each barcode was found in 5 monkeys. Four infected animals were treated with combination antiretroviral therapy (cART) for 82 days starting on day 6 post-infection (study 1). Plasma viremia was reduced from >10(6) to <15 vRNA copies/mL by the time treatment was interrupted. Virus rapidly rebounded following treatment interruption and between 87 and 136 distinct clonotypes were detected in plasma at peak rebound viremia. This study confirmed that SIVmac239M viremia could be successfully curtailed with cART, and that upon cART discontinuation, rebounding viral variants could be identified and quantified. An additional 6 animals infected with SIVmac239M were treated with cART beginning on day 4 post-infection for 305, 374, or 482 days (study 2). Upon treatment interruption, between 4 and 8 distinct viral clonotypes were detected in each animal at peak rebound viremia. The relative proportions of the rebounding viral clonotypes, spanning a range of 5 logs, were largely preserved over time for each animal. The viral growth rate during recrudescence and the relative abundance of each rebounding clonotype were used to estimate the average frequency of reactivation per animal. Using these parameters, reactivation frequencies were calculated and ranged from 0.33–0.70 events per day, likely representing reactivation from long-lived latently infected cells. The use of SIVmac239M therefore provides a powerful tool to investigate SIV latency and the frequency of viral reactivation after treatment interruption. |
format | Online Article Text |
id | pubmed-5433785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54337852017-05-26 Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy Fennessey, Christine M. Pinkevych, Mykola Immonen, Taina T. Reynaldi, Arnold Venturi, Vanessa Nadella, Priyanka Reid, Carolyn Newman, Laura Lipkey, Leslie Oswald, Kelli Bosche, William J. Trivett, Matthew T. Ohlen, Claes Ott, David E. Estes, Jacob D. Del Prete, Gregory Q. Lifson, Jeffrey D. Davenport, Miles P. Keele, Brandon F. PLoS Pathog Research Article HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we generated a genetically tagged virus stock (SIVmac239M) with a 34-base genetic barcode inserted between the vpx and vpr accessory genes of the infectious molecular clone SIVmac239. Next-generation sequencing of the virus stock identified at least 9,336 individual barcodes, or clonotypes, with an average genetic distance of 7 bases between any two barcodes. In vitro infection of rhesus CD4+ T cells and in vivo infection of rhesus macaques revealed levels of viral replication of SIVmac239M comparable to parental SIVmac239. After intravenous inoculation of 2.2x10(5) infectious units of SIVmac239M, an average of 1,247 barcodes were identified during acute infection in 26 infected rhesus macaques. Of the barcodes identified in the stock, at least 85.6% actively replicated in at least one animal, and on average each barcode was found in 5 monkeys. Four infected animals were treated with combination antiretroviral therapy (cART) for 82 days starting on day 6 post-infection (study 1). Plasma viremia was reduced from >10(6) to <15 vRNA copies/mL by the time treatment was interrupted. Virus rapidly rebounded following treatment interruption and between 87 and 136 distinct clonotypes were detected in plasma at peak rebound viremia. This study confirmed that SIVmac239M viremia could be successfully curtailed with cART, and that upon cART discontinuation, rebounding viral variants could be identified and quantified. An additional 6 animals infected with SIVmac239M were treated with cART beginning on day 4 post-infection for 305, 374, or 482 days (study 2). Upon treatment interruption, between 4 and 8 distinct viral clonotypes were detected in each animal at peak rebound viremia. The relative proportions of the rebounding viral clonotypes, spanning a range of 5 logs, were largely preserved over time for each animal. The viral growth rate during recrudescence and the relative abundance of each rebounding clonotype were used to estimate the average frequency of reactivation per animal. Using these parameters, reactivation frequencies were calculated and ranged from 0.33–0.70 events per day, likely representing reactivation from long-lived latently infected cells. The use of SIVmac239M therefore provides a powerful tool to investigate SIV latency and the frequency of viral reactivation after treatment interruption. Public Library of Science 2017-05-04 /pmc/articles/PMC5433785/ /pubmed/28472156 http://dx.doi.org/10.1371/journal.ppat.1006359 Text en © 2017 Fennessey et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Fennessey, Christine M. Pinkevych, Mykola Immonen, Taina T. Reynaldi, Arnold Venturi, Vanessa Nadella, Priyanka Reid, Carolyn Newman, Laura Lipkey, Leslie Oswald, Kelli Bosche, William J. Trivett, Matthew T. Ohlen, Claes Ott, David E. Estes, Jacob D. Del Prete, Gregory Q. Lifson, Jeffrey D. Davenport, Miles P. Keele, Brandon F. Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title | Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title_full | Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title_fullStr | Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title_full_unstemmed | Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title_short | Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
title_sort | genetically-barcoded siv facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433785/ https://www.ncbi.nlm.nih.gov/pubmed/28472156 http://dx.doi.org/10.1371/journal.ppat.1006359 |
work_keys_str_mv | AT fennesseychristinem geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT pinkevychmykola geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT immonentainat geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT reynaldiarnold geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT venturivanessa geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT nadellapriyanka geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT reidcarolyn geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT newmanlaura geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT lipkeyleslie geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT oswaldkelli geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT boschewilliamj geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT trivettmatthewt geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT ohlenclaes geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT ottdavide geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT estesjacobd geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT delpretegregoryq geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT lifsonjeffreyd geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT davenportmilesp geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy AT keelebrandonf geneticallybarcodedsivfacilitatesenumerationofreboundvariantsandestimationofreactivationratesinnonhumanprimatesfollowinginterruptionofsuppressiveantiretroviraltherapy |